Sutro Biopharma Net Income 2017-2021 | STRO

Sutro Biopharma net income from 2017 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Sutro Biopharma Annual Net Income
(Millions of US $)
2020 $-32
2019 $-56
2018 $-35
2017 $-20
2016 $2
Sutro Biopharma Quarterly Net Income
(Millions of US $)
2021-09-30 $-31
2021-06-30 $-6
2021-03-31 $-30
2020-12-31 $-60
2020-09-30 $17
2020-06-30 $30
2020-03-31 $-20
2019-12-31 $-15
2019-09-30 $-13
2019-06-30 $-14
2019-03-31 $-14
2018-12-31 $-1
2018-09-30 $-10
2018-06-30 $-12
2018-03-31 $-12
2017-12-31
2017-09-30 $-1
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.720B $0.043B
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90